

Durvalumab CASPIAN

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Benefit for delayed deterioration in global QoL was not significant



Serious and disabling adverse effects



Other adjustments



Durvalumab CASPIAN

FINAL SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies
Therapeutic Indication: First-line treatment of extensive-stage SCLC
Experimental Arm: Durvalumab + Etoposide and either carboplatin or cisplatin
Control Arm: Platinum-etoposide



